Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Conference Chair

Gregory W. Mattingly, MD

Associate Clinical Professor
Washington University School of Medicine
President, Midwest Research Group
President-Elect
APSARD - American Professional Society for ADHD and Related Disorders
St. Louis, Missouri

Disclosures

Gregory W. Mattingly, MD, has the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie, Inc.; Acadia Pharmaceuticals, Inc.; Alkermes, Inc.; Axsome Therapeutics, Inc.; Corium International, Inc.; Eisai, Inc.; Ironshore Pharmaceuticals Inc.; Intra-Cellular Therapies, Inc.; Janssen Pharmaceuticals; Lundbeck, Inc.; Neos Therapeutics, Inc.; Neurocrine Biosciences, Inc.; Noven Pharmaceuticals, Inc.; Otsuka Pharmaceutical Co., Ltd.; Redax; Roche; Rhodes Pharmaceuticals L.P.; Sage Therapeutics, Inc.; Sunovion Pharmaceuticals, Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals North America, Inc.; Teva Neuroscience, Inc.; Tris Pharma, Inc.
Received grants for clinical research from: AbbVie, Inc.; Alkermes, Inc.; Corium International, Inc.; Eisai, Inc.; Intra-Cellular Therapies, Inc.; Ironshore Pharmaceuticals, Inc.; Janssen Pharmaceuticals; Lundbeck, Inc.; Neurocrine Biosciences, Inc.; Noven Pharmaceuticals, Inc.; Otsuka Pharmaceutical Co., Ltd.; Sunovion Pharmaceuticals, Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals North America, Inc.; Tris Pharma, Inc.
Contracted researcher for: AbbVie, Inc.; Acadia Pharmaceuticals, Inc.; Alkermes, Inc.; Akili Interactive Labs, Inc.; Axsome Therapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Emalex Biosciences; Idorsia Pharmaceuticals, Ltd.; Janssen Pharmaceuticals; Karuna; Lumos Labs, Inc.; Medgenics; NLS-1 Pharma AG; Redax; Relmada Therapeutics, Inc.; Roche; Sage Therapeutics, Inc.; Sirtsei Pharmaceuticals Inc.; Sunovion Pharmaceuticals, Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals North America, Inc.; Teva Neuroscience, Inc

Planning Committee

Anita H. Clayton, MD

David C. Wilson Professor and Chair
Department of Psychiatry and Neurobehavioral Sciences
Professor
Clinical Obstetrics and Gynecology
University of Virginia
Charlottesville, Virginia

Disclosures

Anita H. Clayton, MD, has the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie, Inc.; Acadia Pharmaceuticals, Inc.; Alkermes, Inc.; Allergan; AMAG Pharmaceuticals, Inc.; Astellas Pharma, Inc.; Brii Biosciences; Fabre-Kramer Pharmaceuticals, Inc.; Field Trip Health; Janssen Pharmaceuticals; Lundbeck, Inc.; MINDCURE Health Inc.; Ovoca Bio PLC; Praxis Precision Medicines; PureTech Health; S1 Biopharma, Inc.; Sage Therapeutics, Inc.; Takeda Pharmaceuticals North America, Inc.; Vella Bioscience, Inc.; WCG MedAvante-ProPhase
Received grants for clinical research from: Daré Biosciences, Inc.; Endoceutics, Inc.; Janssen Pharmaceuticals; Praxis Precision Medicines; Relmada Therapeutics, Inc.; Sage Therapeutics, Inc..
Stock options for: Euthymics Bioscience, Inc.; S1 Biopharma, Inc.

Faculty

Leslie Citrome, MD, MPH

Clinical Professor
Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, New York

Disclosures

Leslie Citrome, MD, MPH, has the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie, Inc.; Acadia Pharmaceuticals, Inc.; Adamas Pharmaceuticals, Inc.; Alkermes, Inc.; Allergan; Angelini; Astellas Pharma, Inc.; Avanir Pharmaceuticals; Axsome Therapeutics, Inc.; BioXcel Therapeutics; Boehringer Ingelheim Pharmaceuticals, Inc.; Cadent; Eisai, Inc.; Enteris; HLS Therapeutics; Impel NeuroPharma, Inc.; Intra-Cellular Therapies, Inc.; Janssen Pharmaceuticals; Karuna Therapeutics; Lundbeck, Inc.; Lyndra Therapeutics; MedAvante-ProPhase; Merck & Co., Inc.; Neurocrine Biosciences, Inc.; Novartis Pharmaceuticals; Noven Pharmaceuticals, Inc.; Otsuka Pharmaceutical Co., Ltd.; Ovid Therapeutics; Relmada Therapeutics, Inc.; Reviva Pharmaceuticals, Inc.; Sage Therapeutics, Inc.; Sunovion Pharmaceuticals, Inc.; Supernus Pharmaceuticals, Inc.; Teva Pharmaceuticals USA
Served as a speaker or a member of a speakers bureau for: AbbVie, Inc.; Acadia Pharmaceuticals, Inc.; Alkermes, Inc.; Allergan; Angelini; Eisai, Inc.; Intra-Cellular Therapies, Inc.; Janssen Pharmaceuticals; Lundbeck, Inc.; Neurocrine Biosciences, Inc.; Noven Pharmaceuticals, Inc.; Otsuka Pharmaceutical Co., Ltd.; Sage Therapeutics, Inc.; Sunovion Pharmaceuticals, Inc.; Takeda Pharmaceuticals North America, Inc.; Teva Pharmaceuticals USA
Stock options for: Reviva
Owns stock (publicly) in: Bristol Myers Squibb Company; Johnson & Johnson Pharmaceutical Research & Development; Lilly; Merck & Co; Pfizer, Inc.

Michael E. Thase, MD

Professor, Department of Psychiatry
Mood and Anxiety Disorders Treatment and Research Program
University of Pennsylvania
Perelman School of Medicine
Corporal Michael J. Crescenz
Veterans Affairs Medical Center
Philadelphia, Pennsylvania

Disclosures

Michael E. Thase, MD, has the following relevant financial relationships:
Served as an advisor or consultant for: Acadia Pharmaceuticals, Inc.; Akili Interactive Labs, Inc.; Alkermes, Inc.; Allergan; Axsome Therapeutics, Inc.; BioHaven Pharmaceuticals;; Boehringer Ingelheim Pharmaceuticals, Inc.; CatalYm GmbH; Clexio Biosciences; Gerson Lehrman Group; H. Lundbeck A/S; Jazz Pharmaceuticals, Inc.; Janssen Pharmaceuticals; Johnson & Johnson Pharmaceutical Research & Development; Luye Pharma Group; Merck & Co.; Otsuka Pharmaceutical Co., Ltd.; Pfizer, Inc.; Sage Therapeutics, Inc.; Seelos Therapeutics; Sunovion Pharmaceuticals, Inc.; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: Acadia Pharmaceuticals, Inc.; Allergan; AssureRx Health, Inc.; Axsome Therapeutics, Inc.; BioHaven Pharmaceuticals; Intra-Cellular Therapies, Inc.; Johnson & Johnson Pharmaceutical Research & Development; Otsuka Pharmaceutical Co., Ltd.; Takeda Pharmaceuticals North America, Inc.

Editor

John Churchwell, MS, PhD

Medscape, LLC

Disclosures

John Churchwell, MS, PhD, has the following relevant financial relationships: Formerly employed by an ineligible company: Medtronic

Compliance Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

CME / ABIM MOC / CE

Current Perspectives in Mood Disorders

Authors: Gregory W. Mattingly, MD; Anita H. Clayton, MD; Leslie Citrome, MD, MPH; Michael E. Thase, MD
CME / ABIM MOC / CE Released: 12/21/2022
Valid for credit through: 12/21/2023

Start Activity

Credits Available

Physicians - maximum of 1.75 AMA PRA Category 1 Credit(s)™

ABIM Diplomates - maximum of 1.75 ABIM MOC points

Nurses - 1.75 ANCC Contact Hour(s) (0.5 contact hours are in the area of pharmacology)

IPCE - 1.75 Interprofessional Continuing Education (IPCE) credit

You Are Eligible For
- Letter of Completion
- ABIM MOC points

Target Audience and Goal Statement

This activity is intended for psychiatrists, primary care physicians (PCPs), obstetricians/gynecologists (Ob/Gyns), pediatricians, nurse practitioners (NPs), physician assistants (PAs), nurses, and other healthcare providers (HCPs) who provide care to patients with mood disorders.

The goal of this activity is for learners to be better able to screen, diagnose, and provide clinical care to patients with mood disorders.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Recent clinical data on emerging and novel pharmacologic therapies for mood disorders
Have greater competence related to
- The clinical management of patients with major depressive disorder (MDD) experiencing comorbid conditions
- Identifying depressive episodes related to MDD vs bipolar depression
Demonstrate greater confidence in their ability to
- Incorporate interprofessional strategies into MDD and bipolar spectrum care

Disclosures

Conference Chair

Gregory W. Mattingly, MD

Associate Clinical Professor
Washington University School of Medicine
President, Midwest Research Group
President-Elect
APSARD - American Professional Society for ADHD and Related Disorders
St. Louis, Missouri

Disclosures

Gregory W. Mattingly, MD, has the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie, Inc.; Acadia Pharmaceuticals, Inc.; Alkermes, Inc.; Axsome Therapeutics, Inc.; Corium International, Inc.; Eisai, Inc.; Ironshore Pharmaceuticals Inc.; Intra-Cellular Therapies, Inc.; Janssen Pharmaceuticals; Lundbeck, Inc.; Neos Therapeutics, Inc.; Neurocrine Biosciences, Inc.; Noven Pharmaceuticals, Inc.; Otsuka Pharmaceutical Co., Ltd.; Redax; Roche; Rhodes Pharmaceuticals L.P.; Sage Therapeutics, Inc.; Sunovion Pharmaceuticals, Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals North America, Inc.; Teva Neuroscience, Inc.; Tris Pharma, Inc.
Received grants for clinical research from: AbbVie, Inc.; Alkermes, Inc.; Corium International, Inc.; Eisai, Inc.; Intra-Cellular Therapies, Inc.; Ironshore Pharmaceuticals, Inc.; Janssen Pharmaceuticals; Lundbeck, Inc.; Neurocrine Biosciences, Inc.; Noven Pharmaceuticals, Inc.; Otsuka Pharmaceutical Co., Ltd.; Sunovion Pharmaceuticals, Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals North America, Inc.; Tris Pharma, Inc.
Contracted researcher for: AbbVie, Inc.; Acadia Pharmaceuticals, Inc.; Alkermes, Inc.; Akili Interactive Labs, Inc.; Axsome Therapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Emalex Biosciences; Idorsia Pharmaceuticals, Ltd.; Janssen Pharmaceuticals; Karuna; Lumos Labs, Inc.; Medgenics; NLS-1 Pharma AG; Redax; Relmada Therapeutics, Inc.; Roche; Sage Therapeutics, Inc.; Sirtsei Pharmaceuticals Inc.; Sunovion Pharmaceuticals, Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals North America, Inc.; Teva Neuroscience, Inc

Planning Committee

Anita H. Clayton, MD

David C. Wilson Professor and Chair
Department of Psychiatry and Neurobehavioral Sciences
Professor
Clinical Obstetrics and Gynecology
University of Virginia
Charlottesville, Virginia

Disclosures

Anita H. Clayton, MD, has the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie, Inc.; Acadia Pharmaceuticals, Inc.; Alkermes, Inc.; Allergan; AMAG Pharmaceuticals, Inc.; Astellas Pharma, Inc.; Brii Biosciences; Fabre-Kramer Pharmaceuticals, Inc.; Field Trip Health; Janssen Pharmaceuticals; Lundbeck, Inc.; MINDCURE Health Inc.; Ovoca Bio PLC; Praxis Precision Medicines; PureTech Health; S1 Biopharma, Inc.; Sage Therapeutics, Inc.; Takeda Pharmaceuticals North America, Inc.; Vella Bioscience, Inc.; WCG MedAvante-ProPhase
Received grants for clinical research from: Daré Biosciences, Inc.; Endoceutics, Inc.; Janssen Pharmaceuticals; Praxis Precision Medicines; Relmada Therapeutics, Inc.; Sage Therapeutics, Inc..
Stock options for: Euthymics Bioscience, Inc.; S1 Biopharma, Inc.

Faculty

Leslie Citrome, MD, MPH

Clinical Professor
Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, New York

Disclosures

Leslie Citrome, MD, MPH, has the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie, Inc.; Acadia Pharmaceuticals, Inc.; Adamas Pharmaceuticals, Inc.; Alkermes, Inc.; Allergan; Angelini; Astellas Pharma, Inc.; Avanir Pharmaceuticals; Axsome Therapeutics, Inc.; BioXcel Therapeutics; Boehringer Ingelheim Pharmaceuticals, Inc.; Cadent; Eisai, Inc.; Enteris; HLS Therapeutics; Impel NeuroPharma, Inc.; Intra-Cellular Therapies, Inc.; Janssen Pharmaceuticals; Karuna Therapeutics; Lundbeck, Inc.; Lyndra Therapeutics; MedAvante-ProPhase; Merck & Co., Inc.; Neurocrine Biosciences, Inc.; Novartis Pharmaceuticals; Noven Pharmaceuticals, Inc.; Otsuka Pharmaceutical Co., Ltd.; Ovid Therapeutics; Relmada Therapeutics, Inc.; Reviva Pharmaceuticals, Inc.; Sage Therapeutics, Inc.; Sunovion Pharmaceuticals, Inc.; Supernus Pharmaceuticals, Inc.; Teva Pharmaceuticals USA
Served as a speaker or a member of a speakers bureau for: AbbVie, Inc.; Acadia Pharmaceuticals, Inc.; Alkermes, Inc.; Allergan; Angelini; Eisai, Inc.; Intra-Cellular Therapies, Inc.; Janssen Pharmaceuticals; Lundbeck, Inc.; Neurocrine Biosciences, Inc.; Noven Pharmaceuticals, Inc.; Otsuka Pharmaceutical Co., Ltd.; Sage Therapeutics, Inc.; Sunovion Pharmaceuticals, Inc.; Takeda Pharmaceuticals North America, Inc.; Teva Pharmaceuticals USA
Stock options for: Reviva
Owns stock (publicly) in: Bristol Myers Squibb Company; Johnson & Johnson Pharmaceutical Research & Development; Lilly; Merck & Co; Pfizer, Inc.

Michael E. Thase, MD

Professor, Department of Psychiatry
Mood and Anxiety Disorders Treatment and Research Program
University of Pennsylvania
Perelman School of Medicine
Corporal Michael J. Crescenz
Veterans Affairs Medical Center
Philadelphia, Pennsylvania

Disclosures

Michael E. Thase, MD, has the following relevant financial relationships:
Served as an advisor or consultant for: Acadia Pharmaceuticals, Inc.; Akili Interactive Labs, Inc.; Alkermes, Inc.; Allergan; Axsome Therapeutics, Inc.; BioHaven Pharmaceuticals;; Boehringer Ingelheim Pharmaceuticals, Inc.; CatalYm GmbH; Clexio Biosciences; Gerson Lehrman Group; H. Lundbeck A/S; Jazz Pharmaceuticals, Inc.; Janssen Pharmaceuticals; Johnson & Johnson Pharmaceutical Research & Development; Luye Pharma Group; Merck & Co.; Otsuka Pharmaceutical Co., Ltd.; Pfizer, Inc.; Sage Therapeutics, Inc.; Seelos Therapeutics; Sunovion Pharmaceuticals, Inc.; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: Acadia Pharmaceuticals, Inc.; Allergan; AssureRx Health, Inc.; Axsome Therapeutics, Inc.; BioHaven Pharmaceuticals; Intra-Cellular Therapies, Inc.; Johnson & Johnson Pharmaceutical Research & Development; Otsuka Pharmaceutical Co., Ltd.; Takeda Pharmaceuticals North America, Inc.

Editor

John Churchwell, MS, PhD

Medscape, LLC

Disclosures

John Churchwell, MS, PhD, has the following relevant financial relationships: Formerly employed by an ineligible company: Medtronic

Compliance Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 1.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For Nurses

Awarded 1.75 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.50 contact hours are in the area of pharmacology. 

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read about the target audience, learning objectives, and author disclosures.
Study the educational content online or print it out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Psychiatry & Mental Health

CME / ABIM MOC / CE

Current Perspectives in Mood Disorders

Authors: Gregory W. Mattingly, MD; Anita H. Clayton, MD; Leslie Citrome, MD, MPH; Michael E. Thase, MDFaculty and Disclosures

CME / ABIM MOC / CE Released: 12/21/2022

Valid for credit through: 12/21/2023

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Mental Health Crisis and Opportunity!

Do you want to learn how to move the needle in mental health care by tackling stigma? Dr Gregory W. Mattingly takes on this challenging topic and more.
Gregory W. Mattingly, MD

Differentiating MDD and Bipolar Depression: How to Make the Right Diagnosis

Making the right diagnosis can be difficult. Sharpen your clinical skills in differentiating MDD and bipolar depression.
Leslie Citrome, MD, MPH

Managing Clinical Challenges: Case Discussions on Comorbidities With MDD

Comorbidities can complicate diagnosis. Meet the challenge head on with clinical pearls from this discussion.
Anita H. Clayton, MD

Across the Mood Spectrum: Updates in Treatment of MDD and Bipolar Disorder

Are you up to speed on the latest strategies for treating major depressive and bipolar disorder?
Michael E. Thase, MD

Educational Impact Challenge

The goal of this activity is for learners to be better able to screen, diagnose, and provide clinical care to patients with mood disorders.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Page 1 of 7

CME / ABIM MOC / CE Information Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Conference Chair

Gregory W. Mattingly, MD

Planning Committee

Anita H. Clayton, MD

Faculty

Leslie Citrome, MD, MPH

Michael E. Thase, MD

Editor

John Churchwell, MS, PhD

Compliance Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Peer Reviewer

CME / ABIM MOC / CE

Current Perspectives in Mood Disorders

Credits Available

You Are Eligible For

Target Audience and Goal Statement

Disclosures

Conference Chair

Gregory W. Mattingly, MD

Planning Committee

Anita H. Clayton, MD

Faculty

Leslie Citrome, MD, MPH

Michael E. Thase, MD

Editor

John Churchwell, MS, PhD

Compliance Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Peer Reviewer

Accreditation Statements

For Physicians

For Nurses

Instructions for Participation and Credit

Current Perspectives in Mood Disorders

Contents of This CME Activity

Mental Health Crisis and Opportunity!

Differentiating MDD and Bipolar Depression: How to Make the Right Diagnosis

Managing Clinical Challenges: Case Discussions on Comorbidities With MDD

Across the Mood Spectrum: Updates in Treatment of MDD and Bipolar Disorder

Educational Impact Challenge